---
schema_version: "secwatch.filing_event.v1"
accession: "0001641172-25-009939"
form_type: "8-K"
ticker: "DARE"
cik: "0001401914"
company_name: "Dare Bioscience, Inc."
filed_at: "2025-05-13T23:59:59+00:00"
generated_at: "2026-05-21T14:19:46.729001+00:00"
event_type: "earnings"
sentiment: "neutral"
materiality_score: 0.7
calibrated_materiality_score: 0.7
confidence: "high"
source: SEC EDGAR
---

# Daré Bioscience Q1 2025: Cash $10.3M, R&D down 31%, expects first revenue in Q4 2025

## Summary
- Cash and equivalents $10.3M at March 31, 2025; working capital deficit of $9.4M.
- R&D expenses fell 31% YoY to $2.3M; G&A expenses decreased to $2.3M from $2.7M.
- Targeting first revenue in Q4 2025 via Sildenafil Cream as 503B compounded drug; DARE-HRT1 in 2026.
- Ovaprene Phase 3 contraceptive efficacy study ongoing; interim DSMB review scheduled for July 2025.
- Strategy shift: dual path of 503B compounding and FDA approval; aiming for four on-market products by 2026.

## SEC filing metadata
- accession: 0001641172-25-009939
- form_type: 8-K
- ticker: DARE
- cik: 0001401914
- company_name: Dare Bioscience, Inc.
- filed_at: 2025-05-13T23:59:59+00:00
- event_type: earnings
- sentiment: neutral
- materiality_score: 0.7
- calibrated_materiality_score: 0.7
- confidence: high
- sec_items: 2.02, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1401914/000164117225009939/0001641172-25-009939-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1401914/000164117225009939/form8-k.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001641172-25-009939
- JSON: https://secwatch.observer/filing/0001641172-25-009939.json
- Plain text: https://secwatch.observer/filing/0001641172-25-009939.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.